Insider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Purchases $129,600.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young bought 24,000 shares of the company’s stock in a transaction on Monday, January 27th. The stock was bought at an average price of $5.40 per share, with a total value of $129,600.00. Following the completion of the acquisition, the chief financial officer now owns 24,000 shares in the company, valued at $129,600. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

TriSalus Life Sciences Price Performance

TLSI opened at $5.11 on Friday. The firm has a market cap of $155.82 million, a P/E ratio of -2.05 and a beta of 0.51. TriSalus Life Sciences, Inc. has a 52 week low of $3.50 and a 52 week high of $10.42. The business has a fifty day simple moving average of $4.59 and a 200-day simple moving average of $4.75.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TLSI. Canaccord Genuity Group dropped their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Northland Securities began coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target for the company. Cantor Fitzgerald started coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price objective on the stock. Roth Mkm reissued a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Finally, Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, TriSalus Life Sciences currently has an average rating of “Buy” and an average price target of $11.79.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors have recently bought and sold shares of the company. Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences in the third quarter valued at approximately $66,000. Virtu Financial LLC acquired a new stake in TriSalus Life Sciences during the 3rd quarter worth approximately $92,000. Vestcor Inc purchased a new position in TriSalus Life Sciences in the 3rd quarter valued at approximately $108,000. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences in the third quarter worth $184,000. Finally, Geode Capital Management LLC raised its stake in shares of TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares in the last quarter. 2.58% of the stock is owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.